Abstract
Patients with recurrent/metastatic head and neck cancer (R/M SCCHN) may be treated with sequences starting with cetuximab (Cet) regimens (EXTREME /TPEx) followed by nivolumab, or cisplatin/carboplatin + fluorouracil (CT) + pembrolizumab followed by chemotherapy and/or Cet. The sequences starting with Cet schemes represent the therapeutic alternatives with the longest overall survival (OS) published to date in R/M SCCHN. Sequences starting with EXTREME (Cet + CT)) yielded a median OS of 19.4 months, and those starting with TPEx (Cet + cisplatin + docetaxel + granulocyte colony-stimulating factor) achieved 21.9 months.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
